Literature DB >> 11850859

Survival of patients with pulmonary tuberculosis: clinical and molecular epidemiologic factors.

Kris K Oursler1, Richard D Moore, William R Bishai, Susan M Harrington, Diana S Pope, Richard E Chaisson.   

Abstract

Using restriction fragment-length polymorphism data, we conducted a retrospective cohort study of 139 adult patients with pulmonary tuberculosis to investigate the clinical impact of Mycobacterium tuberculosis infection with a clustered isolate. The cumulative all-cause mortality rate during treatment was 21%. Patients with clustered DNA fingerprint patterns had a reduced risk of death, compared with patients with unique patterns (hazard ratio [HR], 0.5; 95% confidence interval [CI], 0.2-1.1), but this finding was confounded by age (adjusted HR, 0.8; 95% CI, 0.4-1.8). After adjustment for age, the strongest predictors of death were such underlying illnesses as diabetes mellitus, renal failure, chronic obstructive pulmonary disease, and human immunodeficiency virus infection. We conclude that comorbidity and immunosuppression are important predictors of survival for patients with pulmonary tuberculosis in an inner-city cohort. Recently transmitted infection, as determined by use of DNA fingerprinting to classify patients' isolates as being either clustered or unique, was not independently associated with death.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11850859     DOI: 10.1086/338784

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  54 in total

1.  Convergence of the tuberculosis and diabetes epidemics: renewal of old acquaintances.

Authors:  Blanca I Restrepo
Journal:  Clin Infect Dis       Date:  2007-07-05       Impact factor: 9.079

Review 2.  Tuberculosis and diabetes mellitus: convergence of two epidemics.

Authors:  Kelly E Dooley; Richard E Chaisson
Journal:  Lancet Infect Dis       Date:  2009-12       Impact factor: 25.071

Review 3.  Immunological mechanisms contributing to the double burden of diabetes and intracellular bacterial infections.

Authors:  Kelly Hodgson; Jodie Morris; Tahnee Bridson; Brenda Govan; Catherine Rush; Natkunam Ketheesan
Journal:  Immunology       Date:  2015-02       Impact factor: 7.397

4.  Empirical treatment with a fluoroquinolone delays the treatment for tuberculosis and is associated with a poor prognosis in endemic areas.

Authors:  J-Y Wang; P-R Hsueh; I-S Jan; L-N Lee; Y-S Liaw; P-C Yang; K-T Luh
Journal:  Thorax       Date:  2006-06-29       Impact factor: 9.139

5.  Diabetes mellitus and risk of all-cause mortality among patients with tuberculosis in the state of Georgia, 2009-2012.

Authors:  Matthew J Magee; Mary Foote; David M Maggio; Penelope P Howards; K M Venkat Narayan; Henry M Blumberg; Susan M Ray; Russell R Kempker
Journal:  Ann Epidemiol       Date:  2014-02-08       Impact factor: 3.797

Review 6.  Revised guidelines for the diagnosis and control of tuberculosis: impact on management in the elderly.

Authors:  Paul Van den Brande
Journal:  Drugs Aging       Date:  2005       Impact factor: 3.923

Review 7.  Is there an effect of glucose lowering treatment on incidence and prognosis of tuberculosis? A systematic review.

Authors:  Marit Eika Jørgensen; Daniel Faurholt-Jepsen
Journal:  Curr Diab Rep       Date:  2014-07       Impact factor: 4.810

Review 8.  Tuberculosis and its incidence, special nature, and relationship with chronic obstructive pulmonary disease.

Authors:  Biswajit Chakrabarti; Peter M A Calverley; Peter D O Davies
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2007

9.  Deaths among tuberculosis cases in Shanghai, China: who is at risk?

Authors:  Xin Shen; Kathryn Deriemer; Zheng'an Yuan; Mei Shen; Zhen Xia; Xiaohong Gui; Lili Wang; Jian Mei
Journal:  BMC Infect Dis       Date:  2009-06-17       Impact factor: 3.090

10.  Tuberculosis treatment adherence and fatality in Spain.

Authors:  Joan A Caylà; Teresa Rodrigo; Juan Ruiz-Manzano; José A Caminero; Rafael Vidal; José M García; Rafael Blanquer; Martí Casals
Journal:  Respir Res       Date:  2009-12-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.